e’re witnessing a revolution in healthcare. Artificial intelligence (AI) is giving us the ability to discover new treatments and techniques faster than we would’ve thought possible just a decade ago. Companies like Johnson & Johnson are combining their scientific expertise with the power of AI and machine learning to create new drugs, innovative surgical techniques and groundbreaking next-generation solutions.
It’s an exciting time to be in this field, too. The healthcare AI market is growing rapidly, and it’s creating rewarding—and lucrative—careers, to the tune of an expected $10 billion in revenue by 2024. If you’re looking for a place to apply your love of science and technology in a way that can genuinely impact lives, consider a career at Johnson & Johnson. Here are just some of the ways we’re already using AI to change the game.
When you cross an established name that’s been trusted in medicine for over 100 years with a tech giant that’s already pioneered new ground in AI, you get Verb Surgical, a collaboration between Verily Life Sciences LLC (formerly “Google Life Sciences”) and Ethicon, a medical device company in the Johnson & Johnson family of companies. Together, we’re building a platform to reach new frontiers in robotic surgery.
Robot-assisted surgery is nothing new. In fact, an estimated 600,000 robotic surgeries occur each year in the United States. But the platform we’re developing with Verb may one day support tens of millions of robotic surgeries around the world.
That’s because the systems we're creating go beyond just assisting with surgical procedures. Instead, these systems gather and analyze vital information to guide surgeons, which ensures better outcomes for patients. While the very best surgeons in the world provide an unmatched level of skill and experience, Verb Surgical aims to improve the work of all surgeons by sharing analytics and informatics that can lead to better processes and procedures—not to mention results—for doctors and patients.
Parents—especially new and expecting parents—know just how many details there are to learn and manage when it comes to their baby’s health. Like the rest of us, babies have their own unique breathing habits and sleeping patterns that can give us signals about their health, and we’ve been coming up with new ways to learn more about these complicated new humans. By using AI to monitor, quantify and analyze those details, we can personalize healthcare for individual babies.
Johnson & Johnson is collaborating with Rest Devices, a global leader in infant sleep monitoring, to create products that can help parents customize their baby’s care. One of these products is Nod™, an app that tracks the sleeping habits and patterns of infants and gives recommendations on feedings and naps based on details like age and development. Another product, Mimo Baby, is wearable tech (in the form of a onesie) that tracks data like body temperature and breathing. By individualizing AI to learn about each baby, these products help parents become much more informed about their little one’s healthcare needs.
Once upon a time, baby monitors were the norm. Today, we’re giving families innovative new ways to monitor their babies’ health much more closely than just listening from the next room.
AI in Alzheimer’s Disease
We’re also learning that monitoring neuropsychological details can potentially lead to breakthroughs in treating Alzheimer’s disease. Janssen Research & Development, LLC, another organization in the Johnson & Johnson family of companies, has been working with WinterLight Labs and their speech-based AI platform to analyze Janssen’s growing collection of speech data acquired from ongoing clinical trials.
The WinterLight software uses speech-based smart tech to detect and record over 400 quantifiable variables in a patient’s speech. By analyzing the complexity, articulation and content of these variables, we can learn and articulate the differences in how speech affects those with Alzheimer’s, as well as those with other cognitive impairment disorders like Parkinson’s and multiple sclerosis. People with Parkinson’s and MS tend to be as neurologically healthy as most seniors, while those with Alzheimer’s tend to use more pronouns and fewer complex words, and take longer pauses between words.
By combining these two powerful tools from these two innovative companies, we hope to use Janssen’s data and WinterLight’s technology to eventually be able to predict dementia and other neurodegenerative disorders by monitoring the linguistic diversity of patients.
Though AI was once the stuff of science fiction, we’ve recently seen a flood of AI-based innovations that stretch the boundaries of what’s possible in medicine. This is a burgeoning field, and many brilliant minds at ambitious companies like ours are looking for new ways to apply this technology to the healthcare field. After all, we can’t predict the future—but we can make it healthier.
If you’re ready to find a challenging, rewarding career with measurable positive impact the world over, we’d love to meet you. We’ve got thousands of positions available at Johnson & Johnson locations around the globe. Apply today. We can’t wait to meet you.